Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
CytoDyn (CYDY)
:CYDY
Holding CYDY?
Track your performance easily
CYDY Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.10 - $0.32
Previous CloseN/A
Volume1.91M
Average Volume (3M)2.47M
Market Cap
$182.69M
Enterprise ValueN/A
Total Cash (Recent Filing)$1.78M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta-0.23
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding1,227,737,400
10 Day Avg. Volume1,849,828
30 Day Avg. Volume2,471,409
Standard Deviation0.36
R-Squared0.00024
Alpha0.01
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-12.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
CytoDyn News
Options Prices
Currently, No data available
---
Ownership Overview
5.11%
Insiders
―
Mutual Funds
<0.01% Other Institutional Investors
94.88% Public Companies and Individual Investors
CYDY FAQ
What was CytoDyn’s price range in the past 12 months?
CytoDyn lowest stock price was $0.10 and its highest was $0.32 in the past 12 months.
What is CytoDyn’s market cap?
CytoDyn’s market cap is $182.69M.
When is CytoDyn’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were CytoDyn’s earnings last quarter?
Currently, no data Available
Is CytoDyn overvalued?
According to Wall Street analysts CytoDyn’s price is currently Overvalued.
Does CytoDyn pay dividends?
CytoDyn does not currently pay dividends.
What is CytoDyn’s EPS estimate?
CytoDyn’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does CytoDyn have?
CytoDyn has 1,227,737,400 shares outstanding.
What happened to CytoDyn’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of CytoDyn?
Currently, no hedge funds are holding shares in CYDY
---
CytoDyn Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-18.91%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
169.23%
Trailing 12-Months
Company Description
CytoDyn
CytoDyn, Inc. is a clinical-stage biotechnology company, which engages in the development of innovative treatments for multiple therapeutic indications based on leronlimab. Its product include HIV, cancer, graft-versus-host disease (GVHD), and PCa test. The company was founded by Allen D. Allen on May 2, 2002 and is headquartered in Vancouver, WA.
---
Technical Analysis
Atea Pharmaceuticals
―
Cyclerion Therapeutics
―
Ovid Therapeutics
―
Tonix Pharma
―
Kura Oncology
―
Bluebird Bio
―
---